BTIG stays Buy on Avalo Therapeutics Inc. (AVTX) in anticipation of Ph2 abdakibart data
Tweet Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $40.00 price target on Avalo Therapeutics Inc. (NASDAQ: AVTX)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
